134 related articles for article (PubMed ID: 34881791)
1. Epithelial-to-mesenchymal transition of tumor cells: cancer progression and metastasis.
Vardas V; Politaki E; Pantazaka E; Georgoulias V; Kallergi G
Int J Dev Biol; 2022; 66(1-2-3):277-283. PubMed ID: 34881791
[TBL] [Abstract][Full Text] [Related]
2. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
[TBL] [Abstract][Full Text] [Related]
3. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.
Raimondi C; Gradilone A; Naso G; Vincenzi B; Petracca A; Nicolazzo C; Palazzo A; Saltarelli R; Spremberg F; Cortesi E; Gazzaniga P
Breast Cancer Res Treat; 2011 Nov; 130(2):449-55. PubMed ID: 21298334
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements.
Kallergi G; Aggouraki D; Zacharopoulou N; Stournaras C; Georgoulias V; Martin SS
Breast Cancer Res; 2018 Jul; 20(1):67. PubMed ID: 29976237
[TBL] [Abstract][Full Text] [Related]
6. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response.
Satelli A; Brownlee Z; Mitra A; Meng QH; Li S
Clin Chem; 2015 Jan; 61(1):259-66. PubMed ID: 25336717
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.
Cierna Z; Mego M; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Cingelova S; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2014 Jun; 14():472. PubMed ID: 24972610
[TBL] [Abstract][Full Text] [Related]
10. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression.
Satelli A; Batth I; Brownlee Z; Mitra A; Zhou S; Noh H; Rojas CR; Li H; Meng QH; Li S
Oncotarget; 2017 Jul; 8(30):49329-49337. PubMed ID: 28521303
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer circulating tumor cells with mesenchymal features-an unreachable target?
Topa J; Grešner P; Żaczek AJ; Markiewicz A
Cell Mol Life Sci; 2022 Jan; 79(2):81. PubMed ID: 35048186
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.
Armstrong AJ; Marengo MS; Oltean S; Kemeny G; Bitting RL; Turnbull JD; Herold CI; Marcom PK; George DJ; Garcia-Blanco MA
Mol Cancer Res; 2011 Aug; 9(8):997-1007. PubMed ID: 21665936
[TBL] [Abstract][Full Text] [Related]
13. EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer.
Serrano MJ; Ortega FG; Alvarez-Cubero MJ; Nadal R; Sanchez-Rovira P; Salido M; Rodríguez M; García-Puche JL; Delgado-Rodriguez M; Solé F; García MA; Perán M; Rosell R; Marchal JA; Lorente JA
Oncotarget; 2014 Sep; 5(17):7486-97. PubMed ID: 25277187
[TBL] [Abstract][Full Text] [Related]
14. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
[TBL] [Abstract][Full Text] [Related]
15. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
[TBL] [Abstract][Full Text] [Related]
16. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2017 Jul; 28(7):1523-1531. PubMed ID: 28633480
[TBL] [Abstract][Full Text] [Related]
17. The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study.
Yang L; Lv Z; Xia W; Zhang W; Xin Y; Yuan H; Chen Y; Hu X; Lv Y; Xu Q; Weng X; Ni C
Clin Transl Oncol; 2018 Jul; 20(7):912-921. PubMed ID: 29243075
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
[TBL] [Abstract][Full Text] [Related]
19. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
[TBL] [Abstract][Full Text] [Related]
20. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
